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Abstract
Background: Lymphedema and chronic edema is a major health care problem in both developed and non-
developed countries The Lymphoedema Impact and Prevelance - International (LIMPRINT) study is an in-
ternational health service-based study to determine the prevalence and functional impact in adult populations of
member countries of the International Lymphoedema Framework (ILF).
Methods and Results: A total of 1051 patients from eight centers in Turkey were recruited using the LIM-
PRINT study protocol. Data were collected using the core and module tools that assess the demographic and
clinical properties as well as disability and quality of life (QoL). Most of the Turkish patients were recruited
from specialist lymphedema services and were found to be women, housewives, and having secondary lym-
phedema because of cancer treatment. The duration of lymphedema was commonly <5 years and most of them
had International Society of Lymphology (ISL) grade 2 lymphedema. Cellulitis, infection, and wounds were
uncommon. The majority of patients did not get any treatment or advice before. Most of the patients had impaired
QoL and decreased functionality, but psychological support was neglected. Although most had social health
security access to lymphedema centers, nevertheless access seemed difficult because of distance and cost.
Conclusion: The study has shown the current status and characteristics of lymphedema patients, treatment
conditions, the unmet need for the diagnosis and treatment, as well as burden of the disease in both patients and
families in Turkey. National health policies are needed for the prevention, diagnosis, and treatment in Turkey
that utilize this informative data.
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Introduction
Lymphedema is an incurable, debilitating, and progres-sive condition, characterized by persistent swelling of
one or more parts of the body, because of the impairments in
lymph transport. This chronic and progressive disease can
occur at any time after cancer surgeries, can arise from
congenital malformation of the lymphatic system, or because
by damage to lymphatic vessels.1,2 It is a major health care
problem in both developed and nondeveloped countries. It is
serious because of its long-term physical and psychosocial
consequences for the patients, if left untreated. When lym-
phedema is not diagnosed and treated in the earlier stages, the
prognosis for these patients is worse and treatments are more
costly. Lymphedema frequently leads to physical, emotional,
and psychological challenges and impairs the quality of life
(QoL) if it is underrecognized and undertreated.3,4 Treatment
cost of lymphedema has also been identified as a barrier. The
support and funding of medical conditions and complex care
needs will ease the stress and treatment burden associated
with lymphedema.5 There are also challenges of managing
complex lymphedema patients with obesity, and those asso-
ciated with chronic medical conditions and wounds.6 There-
fore the awareness of this chronic condition by both health
professionals and patients—knowledge comprising the char-
acteristics of lymphedema patients, difficulties finding appro-
priate treatments or funding for care, and the impact of disease
on functional, psychosocial status, and QoL are of great im-
portance, especially in developing countries.
Lymphedema has been a rising condition in Turkey over
the past 10–12 years. Awareness about lymphedema was low
and the treatment methods were unknown and certified
lymphedema specialists were lacking until recent years.7
There are no data about the incidence of lymphedema in
Turkey. Patient characteristics or experiences of some pa-
tients are reported in some small studies.7–9
The LIMPRINTª study is an international multisite
health service-based study to determine the prevalence and
functional impact of lymphedema/chronic edema in the
adult population of member countries of the International
Lymphoedema Framework (ILF). It aims to estimate the
proportion of patients with chronic edema and those with a
concurrent wound.
Turkey has been a member of the ILF since 2017 under the
auspices of the Anatolian/Turkish Lymphedema Association
(ALA), but the LIMPRINT study was first noticed by Dr.
Borman, Chair of the ALA at the ILF Meeting in Glasgow, 2014
(www.ilfconference.org). She was influenced by the presenta-
tions from other countries and was interested to find out how a
study of Turkish lymphedema patients could be made and
compare it with different countries. The participation in LIM-
PRINT study would be valuable and provide important infor-
mation about the demographic, social, and QoL characteristics
of Turkish patients. The study results would show the current
status and characteristics of lymphedema patients, treatment
conditions, the unmet need for diagnosis and treatment of those
suffering with the condition, and burden of the disease in both
patients and families in Turkey. The LIMPRINT study would
also allow the comparison with different populations from dif-
ferent countries. In addition the data would be informative for
developing national health polices and reimbursement proce-
dures in diagnosis and treatment of lymphedema in Turkey.
Materials and Methods
Considering all these points, an interest in being part of
LIMPRINT was shared with the executive members of ALA,
and after unanimous approval, a request for Turkey to be in-
volved was officially made in 2014 and accepted by the ILF.
Two main institutions are related to lymphedema in
Turkey: Anatolian Lymphedema Association and Hacettepe
University Lymphedema Practice and Research Center.
Therefore the participation in this international multicenter
study proposal was sent to the health professional delegates
of the ALA from different parts of Turkey working in centers
who are managing patients with lymphedema. In addition,
Hacettepe University Lymphedema Practice and Research
Table 1. The Core Data of Turkish Patients
Comprising the Demographic
and Disease-Related Variables (N = 051)
n (%)
Type of facility
Acute inpatient 53 (5.04)
Acute outpatient 426 (40.53)
General practitioner 1 (0.10)
Nursing home 2 (0.19)
Specialist Lymphoedema Centre 569 (54.14)
Gender
Female 980 (93.24)
Male 71 (6.76)
Age
Mean (minimum, maximum) 53.42 (7–85)
Median 54
Age groups, years
5–14 5 (0.48)
15–44 231 (21.98)
45–64 615 (58.52)
65–74 161 (15.32)
75–84 38 (3.62)
85 plus 1 (0.10)
Obesity
Under weight 14 (1.33)
Normal weight 630 (59.94)
Obese 357 (33.97)
Morbidly obese 50 (4.76)
Lower limb mobility
Bed bound 10 (0.95)
Chair bound 13 (1.24)
Walks with aid 71 (6.76)
Walks unaided 957 (91.06)
Upper limb mobility
No function 3 (0.29)
Limited range of movement 138 (13.13)
Full range of movement 910 (86.58)
Comorbidity
Diabetes mellitus 210 (19.98)
Heart failure/ischemic heart disease 84 (7.99)
Neurological disease 33 (3.14)
Peripheral arterial disease 115 (10.94)
None of these 711 (67.65)
Subjective control of swelling
Yes 393 (48.70)
No 414 (51.30)
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Center actively engaged and recruited a great number of patients
in collaboration with the Department of Physical Medicine and
Rehabilitation. Vascular surgeons and nurses were also in-
formed. Most of the surgeons were not interested in joining the
study. After this initial information the proposal was sent to 10
centers with 8 accepting to be part of the study.
The local steering groups were Anatolian (Turkish)
Lymphedema Association and Hacettepe University Lym-
phedema Practice and Research Center. The stakeholders
were as follows, from five different areas of the country:
(1) University of Hacettepe Faculty of Medicine De-
partment of Physical Medicine and Rehabili-
tation (PMR) and Hacettepe University Lymphedema
Research and Practice Center (Dr. Pınar Borman, Dr.
Merve Denizli, Dr. Aysxegu¨l Yaman, Dr. Oya O¨zde-
mir, Dr. Fusun Terziog˘lu, and Aysxe Arikan Do¨nmez).
(2) Ankara Rehabilitation Training and Research Hospi-
tal (Dr. Meltem Vural, Dr. Sibel U¨nsal Delialiog˘lu).
(3) Ankara Training and Research Hospital Clinic of
PMR (Dr. Figen Ayhan, Dr. Burcu Duyur Cxakıt,
Dr. Sec¸il Vural).
(4) Kirsehir Ahi Evran University Department of PMR
(Dr. Eda Kurt).
(5) Ege University Medical Faculty Department of PMR,
_Izmir (Dr. Sibel Eyigo¨r).
(6) Istanbul Rehabilitation Training and Research Hos-
pital Clinic of PMR (Dr. Evrim Cosxkun Cxelik).
(7) Istanbul Kanuni Sultan Su¨leyman Education and
Research Hospital (Dr. Muge Kepekc¸i).
(8) Manisa Celal Bayar University Medical Faculty De-
partment of PMR (Lale Cerrahog˘lu).
All centers gained approval from their local ethical com-
mittees. The coordinator of the Turkish study was the chair of
ALA and director of the HU Lymphedema Practice and Re-
search Center—P.B. All the LIMPRINT questionnaires were
translated to Turkish and back translated to ensure accuracy of
language. The QoL questionnaires lymphedema quality of life
(LYMQOL)-arm and LYMQOL-leg10 did not have Turkish
validation. The cross-cultural Turkish validation studies of the
LYMQOL-arm and LYMQOL-leg questionnaires were per-
formed before this study began adding further validity to the
methods.11,12 Then the Turkish data collection forms were sent
Table 2. The Turkish Edema Characteristics in the Core Tool (N = 051)
Total (N = 1051) Female (n = 980) Male (n = 71) v2 (df) or p-value
Classification
Primary 152 (14.48) 129 (13.18) 23 (32.39) 19.75 (1)
Secondary 898 (85.52) 850 (86.82) 48 (67.61) <0.001
Secondary swelling
Cancer 717 (79.58) 698 (81.92) 19 (38.78) 53.09 (1)
Noncancer 184 (20.42) 154 (18.08) 30 (61.22) <0.001
Cancer-related secondary LE
Treatment related 715 (99.72) 696 (99.71) 19 (100.0) 0.99a
Metastatic 8 (1.12) 7 (1.00) 1 (5.26) 0.19a
Noncancer-related secondary LE
Venous 92 (50.0) 71 (46.10) 21 (70.00) 0.017
Immobility 48 (26.09) 36 (23.38) 12 (40.00) 0.058
Obesity 84 (45.65) 74 (48.05) 10 (33.33) 0.14
Lymphatic filariasis 5 (2.72) 4 (2.6) 1 (33.3) 0.99a
Noncancer other 57 (30.98) 51 (33.12) 6 (20.00) 0.16
Duration
<6 Months 273 (26.00) 260 (26.56) 13 (18.31)
6 Months to 1 year 128 (12.19) 122 (12.46) 6 (8.45)
1–2 Years 142 (13.52) 133 (13.59) 9 (12.68) 6.64 (5)
2–5 Years 219 (20.86) 201 (20.53) 18 (25.35) 0.25
5–10 Years 146 (13.90) 136 (13.89) 10 (14.08)
10+ Years 142 (13.52) 127 (12.97) 15 (21.13)
History of cellulitis
Yes 232 (22.07) 206 (21.02) 26 (36.62) 9.37 (1)
No 819 (77.93) 774 (78.98) 45 (63.38) 0.002
Infection in last year
Yes 171 (73.71) 149 (72.33) 22 (84.62) 1.80 (1)
No 61 (26.29) 57 (27.67) 4 (15.38) 0.18
Lower limb swelling
Yes 426 (40.57) 367 (37.49) 59 (83.10) 57.12 (1)
No 624 (59.43) 612 (62.51) 12 (16.90) <0.001
Upper limb swelling
Yes 628 (59.81) 615 (62.82) 13 (18.31) 54.56 (1)
No 422 (40.19) 364 (37.18) 58 (81.69) <0.001
aFisher’s exact test.
LE, lymphedema.
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to the included centers. All the centers filled the questionnaires
and sent them by ordinary mail to the coordinator and they
were then returned when completed in batches of 30. Data
entry was undertaken from one center (Hacettepe University)
with each center given an individual code.
The patients were recruited to the study according to the
inclusion and exclusion criteria of the LIMPRINT study
protocol. Data were collected using a Core Tool to determine
the prevalence of chronic edema and a set of five Module
Tools to assess the impact of chronic edema on the lives of
sufferers. Data were entered into a secure central on-line
database. The core tools included questions about type of
facility in which data are collected, demographics, level of
obesity, mobility, relevant comorbidities, classification and
history of lymphedema, cellulitis history, categories of
treatment, site of swelling, wound area, access to treatment,
and subjective control of swelling. The module tools com-
prised demographics and disability, QoL, details of swelling,
wounds, and cancer. The Turkish version of World Health
Organization Disability Assessment Schedule 2.0 (WHODAS
Table 3. The Treatment Categories (N= 051)
All patient (N = 1051),
n (%)
Female (n= 980),
n (%)
Male (n= 71),
n (%)
v2 (df) or
p-value
No treatment offered
No 698 (66.41) 652 (66.53) 46 (64.79) 0.09 (1)
Yes 353 (33.59) 328 (33.47) 12 (35.21) 0.76
Skin care advice
No 552 (52.52) 516 52.65) 36 (50.70) 0.10 (1)
Yes 499 (47.48) 464 (47.35) 35 (49.30) 0.75
Wound dressing
No 1020 (97.05) 957 (97.65) 63 (88.73) 18.40 (1)
Yes 31 (2.95) 23 (2.35) 8 (11.27) <0.001
Antibiotic
No 934 (88.87) 880 (89.80) 54 (76.06) 12.63 (1)
Yes 117 (11.13) 100 (10.20) 17 (23.94) <0.001
Massage
No 594 (56.52) 553 (56.43) 41 (57.57) 0.04 (1)
Yes 457 (43.48) 427 (43.57) 30 (42.25) 0.83
Physiotherapy
No 963 (91.63) 902 (92.04) 61 (85.92) 3.24 (1)
Yes 88 (8.37) 78 (7.96) 10 (14.08) 0.07
Compression garment
No 638 (60.70) 599 (61.12) 39 (54.93) 1.06 (1)
Yes 413 (39.30) 381 (38.88) 32 (45.07) 0.30
Multilayer bandage
No 716 (68.13) 669 (68.27) 47 (66.20) 0.13 (1)
Yes 335 (31.87) 311 (31.73) 24 (33.80) 0.72
Pneumatic compression pumps
No 903 (85.92) 846 (86.33) 57 (80.28) 2.00 (1)
Yes 148 (14.08) 134 (13.67) 14 (19.72) 0.16
Debulking—lipedema—lymphatic surgery
No 1042 (99.14) 971 (99.08) 71 (100.00)
Yes 9 (0.86) 9 (0.92) 0 (0) 0.99a
Exercise advice
No 517 (49.19) 479 (48.88) 38 (53.52) 0.57 (1)
Yes 534 (50.81) 501 (51.12) 33 (46.48) 0.45
Cellulitis advice
No 811 (77.16) 761 (77.65) 50 (70.42) 1.96 (1)
Yes 240 (22.84) 219 (22.35) 21 (29.58) 0.16
Psychological support
No 963 (91.63) 900 (91.84) 63 (88.73) 0.83 (1)
Yes 88 (8.37) 80 (8.16) 8 (11.27) 0.36
Complex decongestive therapy
No 1035 (98.48) 965 (98.47) 70 (98.59) 0.99a
Yes 16 (1.52) 15 (1.53) 1 (1.41)
Control of swelling
No 414 (51.30) 372 (49.80) 42 (70.00) 9.07 (1)
Yes 393 (48.70) 375 (50.20) 18 (30.00) 0.003
aFisher’s exact test.
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2.0) was used to assess disability,13,14 and LYMQOL10–12 and
European Quality of Life Five Dimensional Questionnaire
(EQ-5D)15,16 tools were used to assess QoL.
WHODAS 2.0 is a validated 12-item disability assessment
schedule. It includes questions exploring the patient’s per-
sonal circumstances for example, housing, employment, and
education.14,15
LYMQOL is a validated condition-specific QoL assess-
ment instrument (it is not validated for patients with lym-
phatic filariasis) that assesses the impact of lymphedema on
the patient’s everyday living and health-related QoL. There is
a tool for patients with lymphedema of the upper limb and
one for the lower limb.11–13
EQ-5D is a generic QoL instrument applicable to a wide
range of health conditions and provides a simple descriptive
profile and single index value for health status.15 EQ-5D is
primarily intended for self-completion and is simple and
quick to complete. Turkish validation has previously been
made and used in this study.16
Results
A total of 1051 patients from eight centers of five different
geographical areas took part in the study. Most of the patients
were recruited from specialist lymphedema services. The
majority of patients were women, housewives, nonobese, had
full range of movement, and walked independently. The most
common comorbidity was diabetes followed by hyperten-
sion. Half the patients stated that their edema was not under
control. The core demographic properties of the patients are
given in Table 1.
The classification of lymphedema was mostly secondary
(85%) and caused by cancer (79%) with 85% suffering from
breast cancer, followed by venous insufficiency, lipedema,
immobility, and obesity. The cellulitis and infection or
hospitalization for cellulitis and infection were infrequent.
The duration of lymphedema was <5 years in majority of the
patients. The whole group disease characteristics and dis-
tribution of variables according to gender are given in
Table 2.
The treatment categories of the patients are given in
Table 3. The majority of patients did not get any treatment
or advice before (66.4%). The most common treatment was
exercise (50%), skin care advice (47%), massage (43%), and
compression garment (40%). Psychological support was
neglected in 91% of patients. A great number of patients
expressed that their swelling was not under control. In
Turkey the complex decongestive therapy is free in gov-
ernment hospitals for patients with obligative health insur-
ance. Therefore the majority of the attendants replied to this
question that treatment was free. But the cost of bandages
for multilayer short stretch bandaging are not reimbursed
and the amount of compression garments are only partially
reimbursed in Turkey. Nearly 40% of the patients stated that
if the treatment was not free, they could not cover the expenses
for the treatment. Most of the patients suggested that lym-
phedema treatment was available for free within a reasonable
travelling distance, as they are living in big cities or metro-
poles, but more than one third of them declared that the dis-
tance would prevent patients from accessing specialized
centers. As the majority of patients did not have wounds or
complicated lymphedema, they were not related to discharge
from hospital or long stays in care centers (Table 4).
According to the demographics in the module data, most
patients were in the age range of 45–64 years and were
living with their partners or relatives. Eighty percent of the
patients were owner occupiers and 55% had their own ve-
hicle. As most of the patients were housewives, they were
not the main provider for their family. Fifty-two percent of
the attendants had primary school education with only 20%
having a university diploma. As most patients were
housewives (55%), they (92%) did not have to change or
Table 4. The Questions Related to Access, Distance, and Patient Costs of Treatment (n = 009)
Total (%) Female (%) Male (%) v2 (df) or p-value
(1) Are patients’ entire treatment complex decongestive therapy free?
Yes 779 (77.21) 730 (77.49) 49 (73.13) 0.68 (1)
No 230 (22.79) 212 (22.51) 18 (26.87) 0.41
(2) If it is not free, could the patient cover the treatment expenses?
Yes 538 (61.14) 504 (61.61) 34 (54.84) 1.11 (1)
No 342 (38.86) 314 (38.39) 28 (45.16) 0.29
(3) Is lymphedema treatment available in a reasonable distance?
Yes 785 (77.95) 753 (80.02) 32 (48.48) 35.69 (1)
No 222 (22.05) 188 (19.98) 34 (51.52) <0.001
(4) Does the distance prevent the patient from accessing a specialist center?
Yes 302 (36.39) 276 (35.84) 26 (43.33) 1.35 (1)
No 528 (63.61) 494 (64.16) 34 (56.67) 0.25
(5) Do patients’ lymphedema/wounds prevent discharge from hospital?
Yes 47 (10.26) 35 (8.47) 12 (26.67) 14.58 (1)
No 411 (89.74) 378 (91.53) 33 (73.33) <0.001
(6) Is the patient’s lymphedema/wound the main reason for remaining in long-term care?
Yes 79 (17.59) 63 (15.40) 16 (40.00) 15.20 (1)
No 370 (82.41) 346 (84.60) 24 (60.00) <0.001
(7) Is the patient’s lymphedema/wound the main reason for remaining in long-term home care?
Yes 50 (11.47) 40 (10.05) 10 (26.32) 9.04 (1)
No 386 (88.53) 358 (89.95) 28 (73.68) 0.003
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stop their job/work that would affect their family income
(Table 5).
The details of swelling in the module data are given in
Table 6. The site of swelling was the upper extremity (arms)
in 59% followed by legs (39.8%), Overall 55% did not have
pitting edema. Tissues in the swollen area were mostly soft
with 41% having a significant shape distortion. Thirty-six
percent of the patients had not been told the reason for the
swelling. Stemmer sign was positive in 75% of patients with
lower extremity and 49% of patients in upper extremity
Table 5. Demographic Characteristics (n = 048)
n (%)
Living with
No one/live alone 109 (10.4)
Partner/spouse 724 (69.1)
Other relative 212 (20.2)
Friend 2 (0.2)
Other 1 (0.1)
Living accommodation
Owner occupier 838 (80)
Public rented 11 (1.1)
Privately rented 189 (18)
Nursing home 5 (0.5)
Hospital 1 (0.1)
Supported living
accommodation
4 (0.4)
Patients who had a car or other vehicle
Yes 582 (55.5)
No 466 (44.5)
Working/job
Employed full time 148 (14.1)
Employed part time 25 (2.4)
Retired 208 (19.8)
Unemployed looking for work 20 (1.9)
Not working because of illness 68 (6.5)
Looking after the house
(housewives)
581 (55.4)
Full or part-time education
or training
15 (1.4)
Other 3 (0.3)
Patients were the main provider
Yes 202 (19.3)
No 846 (80.7)
Age of graduation, mean – SD,
median (minimum to maximum)
16.3 – 4.9, 17 (8–45)
Degree of graduation
None (elementary school) 549 (52.4)
School certificate/diploma 265 (25.3)
University diploma/degree 215 (20.5)
Master’s degree 9 (0.9)
Doctorate 10 (1)
Patients who had to change their
job or education/training
Yes 52 (5)
No 996 (95)
Patients who had to stop work or
education/training
Yes 82 (7.8)
No 966 (92.2)
Patients who had been affected/reduced
their family income because
of the swelling
Yes 99 (9.5)
No 949 (90.6)
SD, standard deviation.
Table 6. Details of Swelling (n = 050)
n (%)
Pitting
Yes 475 (45.2)
No 575 (54.8)
Tissue in swollen area
Soft 715 (68.1)
Hard 335 (31.9)
Shape distortion in the affected limb
Yes 436 (41.5)
No 614 (58.5)
Patients who had been told the reason for the
swelling
Yes 671 (63.9)
No 379 (36.1)
The site of swelling
Arm 617 (59.0)
Leg 416 (39.8)
Both 12 (1.2)
Stemmers sign
Hand—positive 313 (49.3)
Foot—positive 329 (75.8)
Severity of the swelling
ISL stage I 289 (27.5)
ISL stage II 648 (61.7)
ISL stage III 113 (10.8)
ISL, International Society of Lymphology.
Table 7. The Disability and Quality-Of-Life
Scores (n= 050)
Mean – SD Median
Minimum
to maximum
WHODAS overall
scores N = 1050
31.7– 21.8 27.1 0–100
EQ-5D scores
(n = 1050)
0.56– 0.32 0.62 0.59–1
Overall health
scores (n = 1050)
61.2– 20.5 60 0–100
LYMQOL—upper
extremity (n = 630)
Function 17.5– 6.1 16 10–40
Appearance 9.4 – 3.6 9 5–20
Symptoms 12.3– 4 12 6–24
Emotion 11.3– 4.2 11 6–24
Overall 6.6 – 1.8 7 0–10
LYMQOL—lower
extremity (n = 429)
Function 19.1– 6.4 19 8–32
Appearance 17.5– 5.9 17 7–28
Symptoms 11.8– 3.9 11 5–20
Emotion 12.9– 4.5 12 6–24
Overall 5.1 – 2.1 5 0–10
EQ-5D, European Quality of Life Five Dimensional Questionnaire;
LYMQOL, lymphedema quality of life; WHODAS, World Health
Organization Disability Assessment Schedule.
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swelling. The majority had ISL grade 2 swelling (61.7%) and
27.5% had ISL grade 1 lymphedema. The disability and QoL
scores are given in Table 7. Most of the patients had impaired
QoL and decreased functionality. These were prominent es-
pecially in lower limb chronic edema patients.
The cancer data showed the majority (84%) had breast
cancer followed by endometrium (8%), cervix (2.8%), and
ovarian (2.4%) cancers. All but five of them had received
treatment for cancer, with 53% having local cancer and 32%
being in remission. The most common type of cancer treat-
ment was surgery followed by chemotherapy and radiation
therapy. The duration of lymphedema was <5 years in the
majority of the patients (88.8%). Twenty-one percent of pa-
tients developed swelling within 3 months, 32% in 3–11
months, and 34% developed in 1–5 years after cancer treat-
ment. The summary of cancer data is given in Table 8.
The majority of patients (98%) did not have a wound. Of
the patients with wounds, 55% had one to two wounds mostly
grade 2 small venous ulcers with low exudate located in the
legs. Most patients looked after their own wounds followed
by physicians and hospital nurses. Nearly half of the wounds
Table 8. Details of Cancer (n = 15)
N (%)
Patients who had treatment for cancer
Yes 710
No 5
Duration between swelling and cancer
treatment (How long after the cancer
treatment did you develop swelling
in the affected area?)
<3 Months 152 (21.3)
3–11 Months 234 (32.7)
1–5 Years 249 (34.8)
6–9 Years 40 (5.6)
10+ Years 32 (4.5)
Unknown 5 (0.7)
Not applicable 3 (0.4)
Current cancer status
Cured/remission 229 (32.0)
Local cancer 383 (53.6)
Distant metastases 56 (7.8)
Do not know 47 (6.6)
Type of cancer
Bladder cancer 2 (0.3)
Breast cancer 603 (84.3)
Cervical cancer 20 (2.8)
Colorectal cancer 2 (0.3)
Endometrial cancer 57 (8.0)
Head and neck cancer 1 (0.1)
Melanoma cancer 6 (0.8)
Ovarian cancer 17 (2.4)
Vulval cancer 2 (0.3)
Other cancer 16 (2.2)
Type of cancer treatments
Surgery 703 (98.3)
Radiation therapy 569 (79.6)
Chemotherapy 595 (83.2)
Hormone therapy 306 (42.8)
Molecular target therapy 16 (2.2)
Other 1 (0.1)
Table 9. Details of Wounds (n = 1)
N (%)
Provider wound care
Physician 13 (61.9)
Podiatrist 0
Self-care 14 (66.7)
Family/friend 6 (28.6)
Hospital nurse 11 (52.4)
Practice nurse 0
Care home nurse 2 (9.5)
Wound care specialist nurse 0
Home care/community nurse 1 (4.8)
Lymphedema specialist nurse/therapist 1 (4.8)
Other 0
No. of wounds
One 7 (33.3)
Two 9 (42.9)
Three 2 (9.5)
Four 1 (4.8)
Five 1 (4.8)
Six 1 (4.8)
Missing 1 (4.8)
Pressure ulcer
None 13
Grade 1 0
Grade 2 5 (62.5)
Grade 3 2 (25.0)
Grade 4 1 (12.5)
Leg/foot ulcer cause
No leg/foot ulcer 6
Venous ulcer 6 (40.0)
Arterial ulcer 1 (6.7)
Mixed (venous/arterial) 1 (6.7)
Neuropathic 1 (6.7)
Neuroischemic 0
Other foot ulcer 2 (13.3)
Do not know ulcer type 7 (46.7)
Acute/surgical wound
No acute/surgical wound 10
Primary closure 0
Open surgical wound 0
Postsurgical breakdown 2 (18.2)
Dehisced wound 5 (45.5)
Traumatic wound 2 (18.2)
Do not know wound type 2 (18.2)
Exudate level
None 9 (42.9)
Low 7 (33.3)
Medium 4 (19.1)
High 1 (4.8)
Location of the wounds
Head or neck 21 (100)
Arms 21 (100)
Chest 19 (90.5)
Abdomen 21 (100)
Back 20 (95.2)
Sacrum 21 (100)
Hips 21 (100)
Upper leg 20 (95.2)
Groin 21 (100)
Lower leg/ankle 9 (42.9)
Foot 14 (66.7)
Other 20 (95.2)
(continued)
208 BORMAN ET AL.
did not have signs of infection (47%) and had been present <6
months in the majority of the patients (70%). The wound
details are given in Table 9.
One of the fundamental aims of the ILF is to support
countries in the development of data to establish the size of
the problem of chronic edema. Such data are essential in
supporting the introduction of evidence-based practice and
enabling each national framework to argue for appropriate
financing and reimbursement.17 According to the aims of
LIMPRINT as an international epidemiological research
study; the preliminary demographic results of this study
provided evidence-based data for the demographic and
clinical properties of Turkish lymphedema patients. The
LIMPRINT study brought a great opportunity and vision to
our community. The reimbursement of pressure garments
was very low in grades 2 and 3 lymphedema patients in
Turkey. The ALA have prepared a file for reimbursement of
care about the condition and impact of lymphedema based on
the results of the LIMPRINT-Turkey study. As a partner of
the ILF and of the LIMPRINT study, ALA have summarized
and indicated the characteristics of Turkish lymphedema
patients and demonstrated their efforts for increasing the
awareness and collaboration between health professionals on
a national basis. The Turkish Social Security Institution has
had meetings with ALA members, made rectification, and
taken the decision to pay more for the reimbursement of
pressure garments for lymphedema patients with grades 2 and
3 lymphedema. We believe that the final data indicate not
only the size of the problem but also the impact of chronic
edema on patient lives in terms of functionality and QoL.
This will assist lymphedema services to provide evidence-
based care. The Turkish LIMPRINT study results demon-
strate that many patients cannot access treatment services
because of the distance and cannot afford to pay for costly
treatments as these are not completely reimbursed. We hope
this evidence-based data will change the national policies for
the care of Turkish patients with lymphedema or chronic
edema.
Conclusion
This final LIMPRINT data reflect that upper extremity
lymphedema is more common than lower extremity and the
major cause is cancer treatment, predominantly breast
cancer in the Turkish LIMPRINT. The most striking results
are that the patients suffer for a long time, most of the pa-
tients have uncontrolled lymphedema mostly grade 2 and
have not received any previous treatment before the study.
Turkish patients had less wounds compared with other
studies undertaken in the LIMPRINT study. This is most
certainly because of the center characteristics that were
rehabilitation services treating a high proportion of cancer
patients, particularly breast cancer, rather than dermatology
or vascular surgery services. The majority of patients had
reduced functional status and decreased QoL. Although most
of the patients had social health security for free complex
decongestive therapy treatment, their ability to access these
centers was more difficult than previously estimated. Na-
tional health policies and planning are needed for the pre-
vention, diagnosis, and treatment of those suffering this
neglected condition in Turkish patients.
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